PTC Therapeutics(DE:BH3)
€57.82-0.02 (-0.03%)
DE:BH3
PTC Therapeutics stock forecast
€57.82
At close:-0.02 (-0.03%)
PTC Therapeutics (BH3) Stock Forecast & Price Target
0 Followers
BH3 Analyst Ratings
Strong Buy
10Buy2Hold0Sell
Based on 12 analysts giving stock ratings to PTC Therapeutics in the past 3 months
BH3 Stock 12 Month Forecast
Average Price Target
€89.68▲(55.10% Upside)Based on 12 Wall Street analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is EUR 89.68 with a high forecast of EUR 122.86 and a low forecast of EUR 55.60. The average price target represents a 55.10% change from the last price of EUR 57.82.
Past 12 Months12 Month ForecastJan2026Oct2026
High€122.86
Average€89.68
Low€55.60
Highest Price TargetHighest€122.86Average Price Target€89.68Lowest Price TargetLowest€55.60
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Brian Cheng | J.P. Morgan | €82.51 | buy | 42.69%Upside | Reiterated | 11/05/26 | ||
| Eliana Merle | Barclays | €109.41 | buy | 89.23%Upside | Reiterated | 11/02/26 | ||
| Eric Joseph | Citi | €96.85→€97.75 | buy | 69.06%Upside | Reiterated | 11/02/26 | ||
| Joon Lee | UBS | €80.71 | buy | 39.59%Upside | Reiterated | 10/30/26 | ||
| Benjamin Burnett | Wells Fargo | €97.75→€100.44 | buy | 73.72%Upside | Reiterated | 10/30/26 | ||
| Joseph Thome | TD Cowen | €80.71→€85.20 | buy | 47.35%Upside | Reiterated | 10/30/26 | ||
| Tazeen Ahmad | Bank of America Securities | ― | buy | ― | Reiterated | 10/30/26 | ||
| Brian Abrahams | RBC Capital | €67.26→€69.05 | hold | 19.43%Upside | Reiterated | 10/29/26 | ||
| Kristen Kluska | Cantor Fitzgerald | €122.86 | buy | 112.49%Upside | Reiterated | 10/29/26 | ||
| Tiago Fauth | Raymond James | €96.85→€95.06 | buy | 64.41%Upside | Reiterated | 10/20/26 | ||
 Alex NackenoffNot Ranked | Truist Financial | €55.60 | hold | -3.84%Downside | Initiated | 10/16/26 | ||
| Basma Radwan | Leerink Partners | €62.78→€87.89 | buy | 52.00%Upside | Initiated | 09/14/26 | ||
| Judah Frommer | Morgan Stanley | €83.40→€93.27 | buy | 61.31%Upside | Reiterated | 07/31/26 | ||
| Paul Choi | Goldman Sachs | €62.78 | sell | 8.57%Upside | Reiterated | 07/30/26 | ||
| Faisal Khurshid | Jefferies | €68.16→€76.23 | buy | 31.84%Upside | Upgraded | 05/27/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Brian ChengJ.P. Morgan | BuyReiterated€82.51 | 11/05/26 | 42.69%Upside | ||
| Eliana MerleBarclays | BuyReiterated€109.41 | 11/02/26 | 89.23%Upside | ||
| Eric JosephCiti | BuyReiterated€96.85→€97.75 | 11/02/26 | 69.06%Upside | ||
| Joon LeeUBS | BuyReiterated€80.71 | 10/30/26 | 39.59%Upside | ||
| Benjamin BurnettWells Fargo | BuyReiterated€97.75→€100.44 | 10/30/26 | 73.72%Upside | ||
| Joseph ThomeTD Cowen | BuyReiterated€80.71→€85.20 | 10/30/26 | 47.35%Upside | ||
| Tazeen AhmadBank of America Securities | BuyReiterated | 10/30/26 | ― | ||
| Brian AbrahamsRBC Capital | HoldReiterated€67.26→€69.05 | 10/29/26 | 19.43%Upside | ||
| Kristen KluskaCantor Fitzgerald | BuyReiterated€122.86 | 10/29/26 | 112.49%Upside | ||
| Tiago FauthRaymond James | BuyReiterated€96.85→€95.06 | 10/20/26 | 64.41%Upside | ||
| Alex NackenoffTruist FinancialNot Ranked | HoldInitiated€55.60 | 10/16/26 | -3.84%Downside | ||
| Basma RadwanLeerink Partners | BuyInitiated€62.78→€87.89 | 09/14/26 | 52.00%Upside | ||
| Judah FrommerMorgan Stanley | BuyReiterated€83.40→€93.27 | 07/31/26 | 61.31%Upside | ||
| Paul ChoiGoldman Sachs | SellReiterated€62.78 | 07/30/26 | 8.57%Upside | ||
| Faisal KhurshidJefferies | BuyUpgraded€68.16→€76.23 | 05/27/26 | 31.84%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering PTC Therapeutics
3 Months
Success Rate14/18 ratings generated profit
78%
Average Return
+15.39%
Copying Tiago Fauth's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +15.39% per trade.
1 Year
Success Rate16/18 ratings generated profit
89%
Average Return
+47.48%
Copying Tiago Fauth's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +47.48% per trade.
2 Years
Success Rate16/18 ratings generated profit
89%
Average Return
+71.33%
Copying Tiago Fauth's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +71.33% per trade.
BH3 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 7 | 9 | 11 | 14 | 13 |
| Buy | 14 | 10 | 10 | 6 | 5 |
| Hold | 5 | 3 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 27 | 23 | 25 | 23 | 21 |
In the current month, BH3 has received 18 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. BH3 average Analyst price target in the past 3 months is 89.68.
BH3 Financial Forecast
High€0.80
Consensus€0.31
Low€-0.38
BH3 Earnings Forecast
Next quarter’s earnings estimate for BH3 is EUR 0.31 with a range of -EUR 0.38 to EUR 0.80. The previous quarter’s EPS was -EUR 0.55. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€311M
Consensus€295M
Low€271M
BH3 Sales Forecast
Next quarter’s sales forecast for BH3 is EUR 295.40M with a range of EUR 271.17M to EUR 311.15M. The previous quarter’s sales results were EUR 319.92M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
BH3 Stock Forecast FAQ
What is DE:BH3’s average 12-month price target, according to analysts?
Based on analyst ratings, PTC Therapeutics’s 12-month average price target is €89.68.
What is DE:BH3’s upside potential, based on the analysts’ average price target?
PTC Therapeutics has 55.10% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PTC Therapeutics a Buy, Sell or Hold?
PTC Therapeutics has a consensus rating of Strong Buy, which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.
What is PTC Therapeutics’s share price target?
The average share price target for PTC Therapeutics is €89.68. This is based on 12 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €122.86, and the lowest forecast is €55.60. The average share price target represents a 55.10% increase from the current price of €57.82.
What do analysts say about PTC Therapeutics?
PTC Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Street analysts.
How can I buy shares of PTC Therapeutics?
To buy shares of DE:BH3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
